Catalyst Crew Technologies Corp. 8-K

What Happened
Catalyst Crew Technologies Corp. announced it completed an asset purchase from its CEO, Kevin Rodan Levy, acquiring AI-enabled healthcare technology assets and related intellectual property. The Asset Purchase Agreement closed on or about February 20, 2026. On March 23, 2026 the company acquired 100% of the issued and outstanding shares of Inversiones Long 33, C.A., making it a wholly owned Venezuelan subsidiary. On April 7, 2026 certain Venezuelan intellectual property rights (previously acquired under the APA) were assigned to that subsidiary as an internal reorganization step.

Key Details

• Asset Purchase Agreement with CEO Kevin Rodan Levy (APA) closed on or about February 20, 2026 (APA dated February 17, 2026 as filed).
• Company acquired proprietary software, machine‑learning models, datasets and IP for CardioAI, PulmoAI, and NeuroAI.
• Share Assignment Agreement dated March 23, 2026: Catalyst Crew acquired 100% of Inversiones Long 33, C.A. as its Venezuela operating entity.
• Intellectual Property Assignment Agreement dated April 7, 2026 transferred Venezuelan registrations to the subsidiary (CardioAI VEN‑SAPI‑2025‑005287; PulmoAI VEN‑SAPI‑2025‑009419; NeuroAI VEN‑SAPI‑2024‑033782). No additional consideration was paid for that assignment.

Why It Matters
This filing documents Catalyst Crew’s acquisition of AI healthcare assets and the creation of a Venezuela operating subsidiary, supporting the company’s Latin American strategy and establishing formal ownership of key AI platforms and local IP. For investors, the material points are ownership of the technology/IP and the new wholly owned foreign subsidiary; the 8‑K does not disclose purchase price, expected financial impact, or integration costs, so monitor future filings and press releases for financial details and operational updates.